Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Lebrikizumab Shows Potential For Biomarker Targeting In Asthma

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase II data published in NEJM show that biomarker-assisted therapies could be valuable in targeting the variabilities of the disease.
Advertisement

Related Content

Personalized Medicine Takes Aim At Common Diseases
Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success
Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success
Roche Pushes Respiratory Agenda In Early Inflammatory Pipeline
Roche Pushes Respiratory Agenda In Early Inflammatory Pipeline
Isis Spin-Off Altair Will Develop Antisense Asthma Candidate 369645

Topics

Advertisement
UsernamePublicRestriction

Register

PS072709

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel